2.1.1.148: thymidylate synthase (FAD)
This is an abbreviated version!
For detailed information about thymidylate synthase (FAD), go to the full flat file.
Word Map on EC 2.1.1.148
-
2.1.1.148
-
medicine
-
tuberculosis
-
dtmp
-
synthases
-
thymidine
-
dihydrofolate
-
maritima
-
bursaria
-
2'-deoxyuridine
-
paramecium
-
folate-dependent
-
chlorella
-
5-substituted
-
virus-1
-
ch2h4folate
-
2'-deoxythymidine-5'-monophosphate
-
flavoenzyme
-
drug development
- 2.1.1.148
- medicine
- tuberculosis
- dtmp
- synthases
- thymidine
- dihydrofolate
- maritima
- bursaria
- 2'-deoxyuridine
-
paramecium
-
folate-dependent
- chlorella
-
5-substituted
-
virus-1
-
ch2h4folate
-
2'-deoxythymidine-5'-monophosphate
-
flavoenzyme
- drug development
Reaction
Synonyms
A674R, complementing thymidylate synthase, FDTS, flavin dependent thymidylate synthase, flavin-dependent thymidylate synthase, flavin-dependent thymidylate synthase X, flavin-dependent TS, Thy1, thymidylate synthase 1, thymidylate synthase complementing protein, thymidylate synthase ThyX, thymidylate synthase X, ThyX, thyX-encoded thymidylate synthase, TSCP, TTHA1096
ECTree
Advanced search results
Application
Application on EC 2.1.1.148 - thymidylate synthase (FAD)
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
drug development
medicine
additional information
unexpected observation that NADP+ competes with both FAD and substrate for the binding site in ThyX and displaces both molecules from the active site, opens avenues for the design of tight-binding inhibitors of ThyX enzymes from a variety of organisms
drug development
-
unexpected observation that NADP+ competes with both FAD and substrate for the binding site in ThyX and displaces both molecules from the active site, opens avenues for the design of tight-binding inhibitors of ThyX enzymes from a variety of organisms
-
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
promising medical target, thyX is present in a number of pathogenic bacteria but absent in human
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low cross-reactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low crossreactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low crossreactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
-
specific and selective inhibitors for thy1 can provide highly effective tools for therapeutic intervention with low crossreactivity against mammalian thyA enzymes, EC 2.1.1.45
medicine
the unique mechanism of FDTS makes it an attractive target for antibiotic drug development
medicine
-
thymidylate synthase as a target for antitubercular drugs
medicine
-
the unique mechanism of FDTS makes it an attractive target for antibiotic drug development
-
autoregulates its own translation, RNA stem-loop structure acts as an inhibitory regulator of translation by preventing the binding of its Shine-Dalgarno-like sequence by positioning it in the stem region, addition of Thy1 into the in vitro translation system also inhibits translation
additional information
-
autoregulates its own translation, RNA stem-loop structure acts as an inhibitory regulator of translation by preventing the binding of its Shine-Dalgarno-like sequence by positioning it in the stem region, addition of Thy1 into the in vitro translation system also inhibits translation
additional information
-
complements the Escherichia coli chi2913 strain that lacks its conventional TS activity, residues Lys165 and Arg168 play critical roles in ThyX activity, possibly by governing access to the carbon atom to be methylated of a totally buried substrate dUMP
additional information
Paramecium bursaria Chlorella virus-1
-
residues His53, Glu190, Arg90, and Arg182 are essential for TS activity